Logo Logo
Hilfe
Kontakt
Switch language to English
Stellenwert der Verlaufsbeobachtung, operativen Tumorresektion und Monochemotherapie bei Oligodendrogliomen WHO Grad II
Stellenwert der Verlaufsbeobachtung, operativen Tumorresektion und Monochemotherapie bei Oligodendrogliomen WHO Grad II
INTRODUCTION Gliomas of histological WHO grades 2 and 3 show a heterogenous prognosis that largely depends on molecular tumor characteristics. Presence of 1p/19q codeletions distinguishes oligodendroglioma from astrocytoma among IDHmut gliomas. Both entities are associated with favourable outcome when compared to IDHwt WHO grade 2 and 3 astrocytomas with molecular features of glioblastomas, e.g., pTERTmut (which are now referred as glioblastoma). We here investigated different therapies in WHO grade 2 oligodendrogliomas (Publication I) and assessed clinical and epigenetic similarities between IDHwt pTERTmut WHO grade 2 and 3 astrocytomas and glioblastoma (Publication II). METHODS In this single-centre, retrospective study, 420 patients were included, including 142 patients with oligodendroglioma, 54 patients with IDHwt astrocytoma WHO grade 2 or 3 with pTERTmut and 224 patients with histopathological glioblastoma. In Publication I, different therapeutic approaches in the treatment of oligodendroglioma WHO grade 2 were investigated, including surveillance strategies after biopsy (wait-and-scan; n=59) or tumor resection (n=27), temozolomide chemotherapy after biopsy (n=26) or the combination therapy of procarbazine, CCNU/lomustine and vincristine (PCV; n=30) after biopsy. In Publication II, extent and pattern of MGMT promoter methylation in IDHwt pTERTmut astrocytomas WHO grade 2 and 3 and in histological glioblastoma were investigated through PCR and Sanger sequencing. RESULTS The retrospective outcome analysis of WHO grade 2 oligodendrogliomas showed superior progression-free survival in patients receiving PCV therapy after biopsy when compared to wait-and-scan or resection only or temozolomide. (in years, 9.1 (PCV) vs 5.1 (wait-and-scan) vs 4.4 (resection) vs 3.6 (temozolomide); p=0.05). Longer progression-free survival in patients treated with PCV when compared to temozolomide was also seen in a matched-pair analysis (p=0.03) and in patients that were treated with PCV or temozolomide at first progression (p=0.04). Histological progression occurred at significantly lower rate in the PCV cohort when compared to all other cohorts (p=0.01). Epigenetic analyses of the MGMT promoter showed similar pattern and extent of methylation in IDHwt pTERTmut astrocytomas and glioblastomas. Overall survival and progression-free survival were similar in both groups irrespective of lower initial histological grade. CONCLUSION PCV chemotherapy prolongs progression-free survival and potentially delays malignant transformation in oligodendroglioma WHO grade 2. Extent and pattern of MGMT promoter methylation in IDHwt pTERTmut astrocytomas and glioblastomas are similar.
Not available
Weller, Jonathan
2022
Deutsch
Universitätsbibliothek der Ludwig-Maximilians-Universität München
Weller, Jonathan (2022): Stellenwert der Verlaufsbeobachtung, operativen Tumorresektion und Monochemotherapie bei Oligodendrogliomen WHO Grad II. Dissertation, LMU München: Medizinische Fakultät
[thumbnail of Weller_Jonathan.pdf]
Vorschau
PDF
Weller_Jonathan.pdf

5MB

Abstract

INTRODUCTION Gliomas of histological WHO grades 2 and 3 show a heterogenous prognosis that largely depends on molecular tumor characteristics. Presence of 1p/19q codeletions distinguishes oligodendroglioma from astrocytoma among IDHmut gliomas. Both entities are associated with favourable outcome when compared to IDHwt WHO grade 2 and 3 astrocytomas with molecular features of glioblastomas, e.g., pTERTmut (which are now referred as glioblastoma). We here investigated different therapies in WHO grade 2 oligodendrogliomas (Publication I) and assessed clinical and epigenetic similarities between IDHwt pTERTmut WHO grade 2 and 3 astrocytomas and glioblastoma (Publication II). METHODS In this single-centre, retrospective study, 420 patients were included, including 142 patients with oligodendroglioma, 54 patients with IDHwt astrocytoma WHO grade 2 or 3 with pTERTmut and 224 patients with histopathological glioblastoma. In Publication I, different therapeutic approaches in the treatment of oligodendroglioma WHO grade 2 were investigated, including surveillance strategies after biopsy (wait-and-scan; n=59) or tumor resection (n=27), temozolomide chemotherapy after biopsy (n=26) or the combination therapy of procarbazine, CCNU/lomustine and vincristine (PCV; n=30) after biopsy. In Publication II, extent and pattern of MGMT promoter methylation in IDHwt pTERTmut astrocytomas WHO grade 2 and 3 and in histological glioblastoma were investigated through PCR and Sanger sequencing. RESULTS The retrospective outcome analysis of WHO grade 2 oligodendrogliomas showed superior progression-free survival in patients receiving PCV therapy after biopsy when compared to wait-and-scan or resection only or temozolomide. (in years, 9.1 (PCV) vs 5.1 (wait-and-scan) vs 4.4 (resection) vs 3.6 (temozolomide); p=0.05). Longer progression-free survival in patients treated with PCV when compared to temozolomide was also seen in a matched-pair analysis (p=0.03) and in patients that were treated with PCV or temozolomide at first progression (p=0.04). Histological progression occurred at significantly lower rate in the PCV cohort when compared to all other cohorts (p=0.01). Epigenetic analyses of the MGMT promoter showed similar pattern and extent of methylation in IDHwt pTERTmut astrocytomas and glioblastomas. Overall survival and progression-free survival were similar in both groups irrespective of lower initial histological grade. CONCLUSION PCV chemotherapy prolongs progression-free survival and potentially delays malignant transformation in oligodendroglioma WHO grade 2. Extent and pattern of MGMT promoter methylation in IDHwt pTERTmut astrocytomas and glioblastomas are similar.